Borosil Scientific Q2FY27: PAT +86% YoY to ₹5.3 Cr, margin expands as pharma losses narrow
PAT +86.37% YoY · revenue +7.55% · margins expanding
₹114.96 Cr
+7.55% YoY
₹5.31 Cr
+86.37% YoY
4.52%
+1.9pp YoY
₹0.6
On a consolidated basis — the primary basis for this group — Borosil Scientific's Q2 FY27 (quarter ended 30 Sept 2026) PAT rose 86.4% YoY to ₹5.31 Cr (EPS ₹0.60 vs ₹0.32) on revenue up 7.5% YoY to ₹114.96 Cr, with NPM expanding to 4.52% from 2.61% and OPM (EBITDA margin) to 9.31% from 7.51% a year ago. But this headline needs an immediate caveat: standalone (parent-only) PAT actually fell 16.9% YoY to ₹6.25 Cr from ₹7.52 Cr, even as standalone revenue grew 4.7% YoY to ₹104.19 Cr — so the consolidated growth is driven almost entirely by subsidiary Goel Scientific Glass Works narrowing its quarterly net loss to ₹0.85 Cr (per the auditor's note) from an estimated ~₹4.7-5.1 Cr a year ago (back-calculated from the Scientific segment's standalone-vs-consolidated gap), not by stronger parent profitability.
Q2 FY-2027 vs prior quarters
The margin bridge has two real, non-subsidiary drivers worth separating from the consolidation effect: the Primary Pharma Packaging segment's loss narrowed to ₹2.60 Cr from ₹5.13 Cr YoY at both standalone and consolidated levels — a genuine structural improvement — while Consumer Glassware revenue fell 10.2% YoY to ₹14.96 Cr with segment profit down to ₹0.78 Cr from ₹1.06 Cr. Working against the group, the standalone Scientific – Lab Glass & Equipment segment's own profit contracted 20.3% YoY (₹18.06 Cr to ₹14.40 Cr segment PBT) despite its revenue growing, pointing to cost or mix pressure in the core parent business that the consolidated optics mask.
The stock went into the print at ₹109.95, down 4.8% over the past month of trading.
No street consensus or formal brokerage preview for this quarter turned up in search, and our records and the filing carry no prior management guidance to grade the print against — both angles are genuinely unavailable rather than skipped. No separate press release was available to cross-check management's own framing of the quarter. The results were approved alongside two capex moves: a ₹70 Cr Borosilicate 3.3 glass tubing furnace (20 MT/day) at Bharuch, intended to backward-integrate tubing currently imported for Pharma Packaging, with commercial production targeted by March 2028; this follows the September 22 announcement of a 7x capacity expansion to 108 lakh units and a separate ₹60 Cr Gujarat facility. Both capex items are funded via internal accruals/borrowings and sit outside this quarter's P&L.
W1
Execution of the ₹70 Cr Bharuch glass-tubing furnace (20 MT/day, commercial production targeted March 2028) — watch capex drawdown pace and any margin uplift to Pharma Packaging once online
W2
Standalone Lab Glass segment profit contracted 20.3% YoY this quarter — watch whether this core-business margin pressure persists or reverses next quarter
W3
Subsidiary Goel Scientific Glass Works' loss narrowed to ₹0.85 Cr this quarter from a much larger year-ago drag — watch whether it continues toward breakeven or re-widens
Figures converted from lakhs; consolidated PAT (530.66L) is pre-NCI 'profit for period', matching the convention used in comparison-context figures. No exceptional item in current or year-ago quarter (H1 FY26's 661.31L VRS exceptional was booked in Q1 FY26). Consolidated includes subsidiary Goel Scientific Glass Works (Q2FY27 net loss 84.87L vs an estimated ~467L loss a year ago per segment-level back-calculation), which materially diverges the consolidated growth story from standalone.